Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
State Street SPDR S&P Biotech ETF
(NY:
XBI
)
152.80
-1.70 (-1.10%)
Streaming Delayed Price
Updated: 11:03 AM EDT, Jul 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about State Street SPDR S&P Biotech ETF
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts
↗
February 24, 2026
According to data from Fiscal AI, Novavax is expected to report a quarterly loss per share of $0.55, higher than the loss of $0.52 reported in the corresponding quarter of 2024.
Via
Stocktwits
Topics
Artificial Intelligence
Earnings
Why Did PVLA Stock Surge 45% In Pre-Market Today?
↗
February 24, 2026
The biotech company reported statistically significant Phase 3 data for QTORIN gel.
Via
Stocktwits
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder
↗
February 23, 2026
The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease.
Via
Stocktwits
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts
↗
February 20, 2026
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.
Via
Stocktwits
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today
↗
January 16, 2026
Via
Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval
↗
January 14, 2026
Via
Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today?
↗
January 14, 2026
Via
Stocktwits
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?
↗
February 20, 2026
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.
Via
Stocktwits
Topics
Earnings
Intellectual Property
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses
↗
February 19, 2026
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said.
Via
Stocktwits
Topics
Artificial Intelligence
Death
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time
↗
February 19, 2026
The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.
Via
Stocktwits
Topics
Artificial Intelligence
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries
↗
February 19, 2026
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.
Via
Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients
↗
January 13, 2026
Via
Stocktwits
Why Did TVTX Stock Crash 30% In Pre-Market Today?
↗
January 13, 2026
Via
Stocktwits
IMRX Stock Closed Over 20% Higher Today: Here’s Why
↗
January 07, 2026
Via
Stocktwits
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
↗
February 18, 2026
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.
Via
Stocktwits
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally
↗
February 18, 2026
The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company.
Via
Stocktwits
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’
↗
February 17, 2026
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks.
Via
Stocktwits
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU
↗
February 13, 2026
Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Via
Stocktwits
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty
↗
February 13, 2026
Ultragenyx said on Thursday that the FDA has again refused approval for UX111 in the treatment of Sanfilippo syndrome type A.
Via
Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline
↗
February 11, 2026
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.
Via
Stocktwits
Biotech Beat Nvidia in 2025. Can It Do It Again?
↗
February 11, 2026
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
Via
The Motley Fool
Topics
Artificial Intelligence
Sector Alert: 4 Healthcare ETFs Poised for Explosive Growth Now
↗
February 11, 2026
Healthcare stocks have lagged the market for years, but 2026 is looking much better.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Economy
Why Did UPB Stock Pop 20% In Pre-Market Today?
↗
February 11, 2026
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.
Via
Stocktwits
Why Did RGNX Shares Plummet 19% After-Hours Today?
↗
February 09, 2026
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.
Via
Stocktwits
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
↗
February 04, 2026
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.
Via
Stocktwits
Topics
Artificial Intelligence
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy?
↗
January 28, 2026
REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.
Via
Stocktwits
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
↗
January 26, 2026
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Via
Stocktwits
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
January 22, 2026
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Initial Public Offering
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?
↗
January 20, 2026
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.
Via
Stocktwits
Why Did GLUE Stock Surge Over 50% In Premarket Today?
↗
January 07, 2026
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
